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Abstract: Hypoxia is a common hallmark of solid tumors and is associated with aggressiveness,
metastasis and poor outcome. Cancer cells under hypoxia undergo changes in metabolism and there
is an intense crosstalk between cancer cells and cells from the tumor microenvironment. This crosstalk
is facilitated by small extracellular vesicles (sEVs; diameter between 30 and 200 nm), including
exosomes and microvesicles, which carry a cargo of proteins, mRNA, ncRNA and other biological
molecules. Hypoxia is known to increase secretion of sEVs and has an impact on the composition of
the cargo. This sEV-mediated crosstalk ultimately leads to various biological effects in the proximal
tumor microenvironment but also at distant, future metastatic sites. In this review, we discuss the
changes induced by hypoxia on sEV secretion and their cargo as well as their effects on the behavior
and metabolism of cancer cells, the tumor microenvironment and metastatic events.
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1. Introduction
Extracellular vesicles are defined as particles, which are delimited by a lipid bilayer and which
cannot replicate [1]. They can be subdivided according to their size into small EVs (≤200 nm; sEVs) and
medium/large EVs (> 200 nm; lEVs) [1]. Both sEV and lEVs have various roles in normal physiology,
notably in development, differentiation, angiogenesis, coagulation, immune modulation, organ
homeostasis and maternal-fetal communication [2]. EVs encompass microvesicles and larger vesicles
such as apoptotic bodies (500 ≤ 2000 nm), released as bulges from apoptotic cells and large oncosomes
(1 ≤ 10 µm), which are derived by the membrane shedding of cancer cells [1,3]. Large oncosomes have
various roles in cancer growth and progression and apoptotic bodies may be involved in intercellular
communication and immune modulation [4,5]. On the other hand, the group of sEVs also covers
exosomes (≤200 nm) derived from late endosomes and small microvesicles (≤200 nm), which are plasma
membrane-derived particles [1] (Figure 1). Microvesicles biogenesis occurs by outward budding of the
plasma membrane and exosome biogenesis takes place by inward budding of multivesicular bodies
(MVB) with the plasma membrane and this fusion results in the formation of intraluminal vesicles
(ILV), which are then released into the extracellular medium [6]. Both exosomes and microvesicles
contain DNA, RNA, proteins, lipids and metabolites. RNA molecules found in these structures include
microRNAs, mRNAs, long non-coding RNAs (lncRNAs) and circular RNAs [6]. Metabolites found in
sEVs consist of amino acids, nucleotides, nucleosides, organic acids, sugars, alcohols, vitamins and
derivatives from lipids (reviewed in [7]). Several databases have been established recently, which
cover the protein and RNA content of exosomes and microvesicles, such as Exocarta, Vesiclepedia
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and EVpedia [8–10]. Since methods are missing to clearly separate exosomes from small microvesicles
(≤200 nm) due to their identical densities [1], this review will focus on both types, named hereafter
small extracellular vesicles (sEVs).
sEVs can deliver their messages into the target cell by several distinct mechanisms: through
non-specific processes such as endocytosis (by macropinocytosis or micropinocytosis [6,11]) or through
the interaction of membrane proteins expressed at the sEV surface with receptors at the surface of the
target cell (reviewed in [6]). The receptor-dependent pathway can involve either a protein, a lipid or a
sugar at the sEV surface [6]. Once the sEV has entered the cell, the current theory is that the vesicle is
fusing with the endosome to release its cargo, which can then be delivered to other compartments of
the cell such as the endoplasmic reticulum or the nucleus [6,12,13].
Tumor sEVs were shown to educate cells at pre-metastatic sites towards a pro-metastatic phenotype.
Thus, sEVs can help cancer cells to metastasize to a new organ [14]. Although there is no evidence for
an indispensable receptor at the surface of the acceptor cell, Hoshino et al. demonstrated that integrins
expressed at the surface of the sEVs could determine in which organ the metastasis would occur [15].
It is known that hypoxia can upregulate the expression of some integrins. However, it remains to be
shown whether hypoxia-induced changes of integrin expression at the surface of sEVs might influence
the location of tumor metastasis [16,17].
Hypoxia is a common feature in many solid cancers and is defined by a lower oxygen tension
compared to physiological conditions. The oxygen tension found in normal tissues is about 30–60 mm
Hg, but can reach low values of around 10 mm Hg in skeletal muscle or in skin [18], while the median
value in tumor cores is ranging between 2 and 16 mm Hg [19]. Intra-tumoral hypoxia is caused by the
lack of blood vessels and the fast growing rate of cancer cells, which adapt to this low tissue oxygenation
by activating the hypoxia-inducible transcription factors (HIFs). The two main HIFs upregulated under
hypoxia are HIF-1α and HIF-2α. Under normoxic conditions, prolyl hydroxylase domain proteins
(PHDs) hydroxylate proline residues on HIF-1α, which allows the binding of von Hippel-Lindau (VHL)
tumor suppressor protein to HIF-1α for subsequent ubiquitination. The ubiquitinated HIF-1α is then
degraded by the 26 S proteasome [19]. In addition, factor inhibiting HIF1 (FIH-1) hydroxylates HIF-1α
on an asparagine residue, which inhibits the interaction of HIF-1α with its coactivators [19]. Under low
oxygen availability, the activity of both PHD and FIH-1 is inhibited, leading to the stabilization and
translocation of HIF-1α to the nucleus. HIF-1α can subsequently trigger the transcription of multiple
target genes, e.g., those encoding vascular endothelial growth factor, carbonic anhydrase 9 or glucose
transporter 1 [19]. HIF-1α is stabilized during acute hypoxia, while under prolonged hypoxia, HIF-2α
is activated [20]. The transcriptional responses mediated by HIFs then activate processes involved in
angiogenesis, invasion and in the metabolic adaptation of cancer cells.
Hypoxia influences the uptake of sEVs. Jung et al. recently demonstrated that hypoxic breast
cancer cells preferentially take up hypoxic sEVs compared to normoxic sEVs [21]. This was confirmed
using sEVs loaded with anticancer drugs to treat hypoxic cancer cells; hypoxic sEVs were more efficient
to kill hypoxic cancer cells compared to normoxic sEVs [21]. In a previous study, we did not see
significant differences in the uptake of normoxic sEVs between melanoma cells grown under normoxia
or hypoxia, but we observed that cells produced more exosomes under hypoxic conditions [22].
Hypoxia generally induces an increase of sEV secretion from cancer cells [22–24] as well as a change
in their cargo, which reflects the status of the cells from which they are derived [22,25,26]. Rab22 a,
a small GTPase and a target gene of HIF-1α and HIF2α, is involved in the production of sEVs [27].
In addition, various stresses encountered by cells under hypoxia, like oxidative stress or low pH,
can also increase sEV secretion [28–31]. Very recently, Patton et al. showed that hypoxia changed the
size distribution of sEVs with a clear trend toward smaller average vesicle size. In pancreatic cancer
cells, hypoxia promoted a time-dependent release of sEVs and only a minimal induction of medium
EVs (mEVs) and large EVs (lEVs) [32].
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Figure 1. Overview of small extracellular vesicles (sEVs), their content, mechanisms of hypoxia
and their potential biological roles. (A) sEVs are constituted of exosomes and small microvesicles.
Exosomes are secreted after fusion of multivesicular bodies (MVB) with the plasma membrane and
microvesicles are released by direct budding from the plasma membrane. sEVs can carry DNA
fragments, mRNAs, microRNAs, lncRNAs, proteins, lipids and all other biological molecules. (B)
Under normal O2 availability, prolyl hydroxylase domain proteins (PHDs) hydroxylate proline residues
on HIF-1α, which triggers the binding of the von Hippel-Lindau (VHL) tumor suppressor protein to
HIF-1α leading to ubiquitination and degradation of HIF-1α. Under hypoxia, HIF-1α is stabilized
and binds hypoxic response elements (HRE), thereby triggering target gene expression. This leads to
changes in the metabolism of the cells and may stimulate invasion and angiogenesis. (C) Hypoxic sEVs
play roles in invasion, migration, angiogenesis, epithelial to mesenchymal transition (EMT) and drug
resistance of cancer cells. They also regulate immune responses, metabolism and hypoxia tolerance of
target cells, details of which are discussed below.
The growth and progression of cancer cells is crucially affected by their interaction with the
surrounding cells in their niche [33]. This niche, or tumor microenvironment (TME), is where cancer
cells interact with stromal cells (fibroblasts and endothelial cells) and immune cells, including natural
killer (NK) cells, dendritic cells, myeloid-derived suppressor cells, T cells and macrophages [33].
Cancer cells and cells from the TME communicate through direct contact between cells, by releasing
cytokines and other soluble factors as well as sEVs [33].
In this review, we will cover the role of hypoxic sEVs produced by either cancer cells or cells from
the TME. We will focus on the role of miRNAs and proteins that have been identified in hypoxic EVs
and their possible effects on migration, invasion, angiogenesis, epithelial to mesenchymal transition
(EMT), immune response pathways, metabolism and resistance to drug treatment.
2. Hypoxic sEVs’ Cargo and Its Role in Key Biological Processes Related to Cancer
2.1. Migration and Invasion of Cancer Cells
The protein cargo of hypoxic cancer sEVs can influence migration, invasion and metastasis
of cancer cells. Matrix metalloproteinase (MMP), especially MMP2, MMP9 and MMP14 activity is
associated with invasion and metastasis of tumor cells (reviewed in [34]). Metalloproteinases degrade
the extracellular matrix (ECM) and thus enhance the invasion of cancer cells [34]. Interestingly, MMP2,
MMP9 and MMP13 levels were increased in sEVs derived from hypoxic prostate cancer cells and
hypoxic nasopharyngeal carcinoma cells [35,36] and exosomal MMP13 has been shown to enhance
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migration and invasion of recipient cells in vitro and in vivo [36]. MMP2 and MMP9 activity and
a number of signaling molecules like transforming growth factor β (TGF-β), tumor necrosis factor
α (TNF-α) and interleukin 6 (IL-6) were increased in hypoxic (compared to normoxic) sEVs [35].
In endothelial cells, MMP2 activity has been shown to be induced by hypoxic sEVs derived from renal
carcinoma cells [37] while MMP14 expression levels were found to be increased in sEVs from hypoxic
pancreatic cells together with C4.4A and α6β4 integrin [38]. C4.4A, a structural homologue of the
urokinase receptor, is enriched in hypoxic sEVs in a HIF-1α-independent way and the association of
C4.4A with α6β4 integrin and MMP14 leads to an increase of motility, due to laminin degradation [38].
In addition, lysyl oxidase (LOX) enzymes, also found enriched in hypoxic sEVs [39], catalyze an
important step of the crosslinking of collagen and also elastin, increasing the stiffness of the ECM and
thereby facilitating cancer cell adhesion and invasion into the ECM (reviewed in [40]). Furthermore,
in ovarian cancer, hypoxic sEVs enriched in CD171 promote cell migration and trigger extracellular
signal-regulated kinase (Erk) phosphorylation [41]. Hypoxic sEVs derived from colorectal cancer
cells contain Wnt4 and promote metastasis of normoxic colorectal cancer cells by enhancing β-catenin
translocation to the nucleus and subsequent activation of the β-catenin signaling pathway, increasing
the migratory and invasive properties of colorectal cancer cells [42]. Taken together, metalloproteinases
and other enzymes modulating the TME, which are transported by sEVs, clearly have an impact on
migration and invasion of cancer cells, thereby modulating their metastatic potential.
In addition to the proteins mentioned above, miRNAs loaded in hypoxic sEVs are also involved
in the transfer of pro-metastatic properties. sEVs derived from hypoxic hepatocellular carcinoma cells
deliver miR-1273f, which increases proliferation and metastasis by targeting LIM Homeobox 6 (LHX6),
an inhibitor of the Wnt/β-catenin pathway [43]. miR-21, secreted in hypoxic sEVs from oral squamous
carcinoma cells, promotes migration and invasion of normoxic cells [24].
An overview of the effects of hypoxic sEVs on key biological processes in the recipient cells
through transfer of oncoproteins, miRNAs and lncRNAs is presented in Figure 2. A summary of the
role of proteins contained in hypoxic sEVs on migration, invasion, angiogenesis and immune response
pathways is provided in Table 1.
Figure 2. Hypoxic sEVs promote progression and metastasis of cancer cells. Hypoxic sEVs enriched with
a disintegrin and metalloproteinase with thrombospondin motifs 1 (ADAMTS1), carbonic anhydrase 9
(CA9), protein-lysine 6-oxidase (LOX), tissue factor (TF), thrombospondin-1 (TSP1), vascular endothelial
growth factor (VEGF), Wnt4, miR-135b, miR-155, miR-210, miR-23a, miR-494 and/or lnc-p21 promote
angiogenesis. Hypoxic sEVs loaded with C4.4A, CD171, α6β4 integrin, matrix metalloproteinases
(MMP2, MMP9, MMP13 and MMP14), protein arginine methyltransferase 5 (PRMT5) and/or miR-1290
drive migration and invasion of target cancer cells. HIF-1α, TGF-β and/or Lnc-UCA1 contained in
hypoxic sEVs can enhance epithelial to mesenchymal transition (EMT). miR-21 and/or miR-1273f,
secreted in hypoxic sEV, promote metastasis of cancer cells.
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Table 1. Proteins enriched in sEVs derived from hypoxic cancer cells.
Protein Cancer Type Biological Effects in Cancer Ref.
C4.4A, α6β4 integrin,
MMP14 Pancreatic cancer Promotes migration [38]
CD171 Ovarian Promotes migration [41]
MMP2, MMP9 Prostate cancer Enhances invasion [35]
MMP13 Nasopharyngeal carcinoma Enhances migration and invasion [36]
PRMT5 Melanoma Promotes migration and invasion [22]





TF Glioma Induces angiogenesis [44]
Wnt4 Colorectal cancer Induces a pro-metastaticphenotype and angiogenesis [42,45]
HIF-1α Nasopharyngeal carcinoma Promotes EMT-related process [46]




carcinoma, lung cancer Immunosuppressive function [47]
TGF-β Lung carcinoma, leukemia,breast cancer
Inhibits NK cells and
T cell proliferation [48,49]
MTA1 Breast cancer Regulates hypoxiaand estrogen signaling [47]
STAT3 Ovarian cancer Promotes chemoresistance [50]
2.2. Angiogenesis
HIF-1α and HIF-2α knockout mice show lethal defects in vascularization, demonstrating an
important role for HIFs in angiogenesis [51–54]. Hypoxic sEVs can promote angiogenesis through
delivery of their cargo to various cells of the TME, affecting the phenotype and the transcriptome
of endothelial cells [55]. Various proteins carried by hypoxic sEVs are involved in the promotion of
angiogenesis, such as protein-lysine 6-oxidase (LOX), thrombospondin-1 (TSP1), vascular endothelial
growth factor (VEGF) and a disintegrin and metalloproteinase with thrombospondin motifs 1
(ADAMTS1), Wnt4, tissue factor (TF) and CA9 (carbonic anhydrase 9) [37,39,42,44]. LOX levels, together
with TSP1, VEGF and ADAMTS1 were found elevated in sEVs derived from hypoxic glioblastoma cells,
driving angiogenesis-related processes in endothelial progenitor cells [39]. Hypoxic colorectal cancer
cells transfer Wnt4 via sEVs to endothelial cells where it activates the β-catenin signaling pathway,
also promoting angiogenesis [42]. TF, which is secreted into sEVs derived from hypoxic glioma cells,
triggers angiogenesis in human umbilical vein endothelial cells by activating protease activate receptor
2 (PAR2), triggering subsequent Erk phosphorylation [44]. Finally, CA9, whose levels were enriched in
sEVs derived from hypoxic renal cell carcinoma, stimulates migration and tube formation of human
umbilical vein endothelial cells [37].
Several miRNAs secreted in sEVs derived from hypoxic cancer cells have been shown to
be involved in angiogenesis. miR-135b contained in sEVs derived from hypoxic drug-resistant
myeloma cells, targets FIH-1 in endothelial cells, thus increasing the activity of HIF-1α and promoting
angiogenesis [56]. In lung cancer, miR-23a and miR-494 within hypoxic sEVs were also shown
to promote angiogenesis [57,58]. mir-23a inhibits expression of the prolyl hydroxylase and tight
junction protein ZO-1, thereby enhancing angiogenesis [57]. mir-494 targets the phosphatase and
tensin homolog protein (PTEN), a negative regulator of the PI3K/Akt pathway, thus increasing levels
of phosphorylated Akt (p-Akt). P-Akt subsequently phosphorylates the endothelial nitric oxide
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synthase (eNOS), leading to an increase of angiogenesis in endothelial cells [58]. sEVs from hypoxic
leukemia cells are enriched with miR-210, the “prototype” of hypoxia-associated miRNAs, inhibiting
Ephrin-A3 expression in endothelial cells and leading to an increase in tube formation [59]. Likewise,
miR-155, enriched in sEVs of hypoxic hepatocellular carcinoma cells, also induces angiogenesis [60].
Apart from the well-known miR-210, we recently identified miR-1290 as a novel hypoxia-associated
miRNA, which was highly abundant in hypoxic melanoma sEVs. On the other hand, miR-23a-5p
and -23b-5p were consistently downregulated in hypoxic conditions, while the protein levels of the
miR-23a/b-5p-predicted target IPO11 were concomitantly upregulated [22]. Furthermore, lncRNAs can
be transferred: hypoxic non-small lung cancer cells transfer lncRNA-p21 via sEVs to endothelial cells,
promoting tube formation and tumor cell adhesion [61]. Overall, a number of miRNAs and lncRNAs
contained in hypoxic sEVs actively shape the migration, invasion, angiogenesis and immune response
pathways (summarized in Table 2). Of note, only a small proportion of the total cellular miRNA pool
is encapsulated into sEVs. In this context, Chevillet et al. analyzed the number of miRNA molecules
per sEV isolated from plasma and found that there is less than one molecule of a particular miRNA per
sEV [62]. One additional study confirmed a low ratio of miRNAs per sEV while another stoichiometric
analysis found more than 10 copies of a given miRNA per sEV [63,64]. However, the high amount
of sEVs secreted by cells in pathophysiological states and/or under hypoxia may compensate for the
potentially low number of miRNAs molecules, still providing functionally relevant amounts of a given
miRNA or family of miRNAs to the recipient cells.
Table 2. miRNAs and lncRNAs enriched in small extracellular vesicles derived from hypoxic cancer cells.
miRNA Target Gene Cancer Type Biological Effects in Cancer Ref.
miR-1290 Not reported Melanoma Promotes migrationand invasion [22]
miR-23a PHD and ZO-1 Lung cancer Promotes migrationand angiogenesis [57]
miR-135b FIH-1 Multiple myeloma Promotes angiogenesis [56]
miR-155 Not reported Hepatocellularcarcinoma
Increases angiogenesis in
endothelial cells [60]
miR-210 Ephrin-A3 Leukemia Increases angiogenesis [59]




miR-21 Not reported Oral squamouscarcinoma
Leads to a pro-metastatic
phenotype [24]









SOCS4/5/STAT3 Ovarian cancer Elicit M2 polarizationof macrophages [67]
miR-301-3p PTEN Pancreatic cancer Mediates M2 polarization ofmacrophages [68]
miR-940 Not reported Epithelialovarian cancer
Promotes M2 polarization of
macrophages [69]
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Table 2. Cont.
miRNA Target Gene Cancer Type Biological Effects in Cancer Ref.








miR-21 PTEN Oral cancer Inhibits the expansion andcytotoxicity of γδ T cells [70]
miR-23a CD107 Lung carcinoma andleukemia Inhibits NK cells [48]
miR-24-3p FGF11 Nasopharyngealcarcinoma
Impairs T cell proliferation
and differentiation of Th1
and Th17 cells
[71]






Lnc-p21 Not reported Non-small celllung cancer Elicits angiogenesis [61]
Lnc-UCA1 Not reported Bladder cancer Enhances EMT [74]




2.3. Epithelial Mesenchymal Transition
Epithelial to mesenchymal transition (EMT) is an important process by which cancer cells evade
their original niche and subsequently invade and migrate towards other tissues [77]. During EMT, cells
lose their epithelial characteristics and gain mesenchymal features [77]. Those changes are accompanied
by the loss or down-regulation of E-cadherin and the increase of β-catenin expression [77]. Loss of
E-cadherin leads to the disruption of cell-to-cell contacts, and other cytoskeletal alterations [77]. In this
context, Ramteke et al. reported that hypoxic sEVs repress the expression of E-cadherin in normoxic
target cells, thus promoting EMT [35]. HIF-1α secreted in sEVs from nasopharyngeal carcinoma cells
was also found to trigger EMT-related processes in recipient cells [46] and signaling molecules such
as TGF-β, transported by hypoxic sEVs [35], support EMT through induction of chromatin changes
(reviewed in [78]). Finally, the lncRNA UCA1, in sEVs of hypoxic bladder cancer cells, promotes EMT
in vitro and in vivo [74].
sEVs do not only carry proteins and RNAs, but also lipids [79]. Hypoxia has been shown to
induce lipid accumulation in cells and sEVs released by hypoxic cancer cells supporting growth and
invasiveness of hypoxic prostate cancer cells following re-oxygenation [80]. Given the large variety of
lipid species, further studies will be needed to investigate the role of lipids contained in sEVs derived
from hypoxic cancer cells or cells from the TME on the progression of cancer in more detail.
2.4. Immune Response Pathways
Hypoxia has been known to play a role in the progression of cancer cells by suppressing the
response of the immune system and by altering the differentiation of immune cells [81], and hypoxic
sEVs are involved in mediating those effects. For example, miR-10 and miR-21 secreted by hypoxic
sEVs derived from glioma cells target RAR-related Orphan Receptor α (Rorα) and PTEN expression,
respectively, in order to repress the myeloid-derived suppressor cells [65].
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Macrophages can differentiate into two main subpopulations: the pro-inflammatory M1
macrophages and the anti-inflammatory M2 macrophages, which promote tumor growth [82]. In a
non-cancerous microenvironment, hypoxia can promote M1 polarization. This is in contrast to the
glioma microenvironment, where hypoxia has been shown to support M2 polarization by upregulating
TGF-β and macrophage colony-stimulating factor receptor (MCSFR) [83,84]. Although there is still no
consensus whether hypoxia promotes M1 or M2 polarization, there are now several reports showing
that hypoxic sEVs promote M2 polarization. miR-1246, enriched in sEVs derived from hypoxic glioma
cells, targets the telomeric repeat-binding factor 2-interacting protein 1 (TERF2IP), which subsequently
downregulates the NFκB pathway and activates the STAT3 pathway, leading to M2 macrophage
polarization [66]. miR-301a-3p levels were increased in hypoxic pancreatic cell-derived sEVs and
transfer of miR-301a-3p to macrophages elicits an M2 phenotype through activation of the PTEN/PI3Kγ
signaling [68]. sEVs of hypoxic melanoma, squamous skin carcinoma and lung cancer cells are loaded
with immunosuppressive proteins like colony-stimulating factor 1 (CSF-1), C-C motif chemokine
2 (CCL2), ferritin heavy chain (FTH), ferritin light chain (FTL) and TGF-β as well as the miRNA
let-7a [47]. The delivery of let-7a increases oxidative phosphorylation and M2 polarization of targeted
macrophages through the downregulation of the insulin-Akt-mTOR pathway by inhibiting expression
of the insulin receptor substrate 1 (IRS1), insulin receptor substrate 2 (IRS2), insulin receptor (INSR)
and insulin-like growth factor 1 receptor (IGF1R), being involved in the insulin signaling pathway [47].
Furthermore, miR-21-3p, miR-125b-5p, miR-181d-5p and miR-940 are loaded in sEVs derived from
hypoxic ovarian cancer cells and also induce the polarization of macrophages towards a tumor-like
M2 phenotype [67,69] by targeting the SOCS4/5/STAT3 signaling pathway [69]. The lncRNA BRCT1,
enriched in breast cancer sEVs was also shown to promote an M2 phenotype in macrophages [75]
and finally, sEVs derived from hypoxic mesenchymal stem cells transfer miR-21-5p, which inhibits
PTEN expression levels, subsequently promoting the differentiation of macrophages towards an M2
phenotype [85].
Natural killer (NK) cells are innate lymphoid cells, which have a strong anti-tumor activity [81].
NK cell function is impaired under hypoxia, which induces a decrease of the expression of several
NK cell receptors responsible for the killing of target cells [81,86]. Berchem et al. have shown that
the transfer of hypoxic tumor sEVs carrying TGF-β and miR-23a has immunosuppressive effects on
NK-cells [48]. TGF-β downregulates the expression of NKG2D, an activating receptor of NK cells
while miR-23a targets CD107a, a marker of NK cell degranulation [48]. Maus et al. have described that
hypoxic melanoma sEVs regulate dendritic cell maturation and affect the cytokines and chemokines
released by dendritic cells [87]. Those studies demonstrate that hypoxia induced-sEVs can alter NK
cell function.
γδ T cells, a particular class of T cells containing T cell receptors (TCRs) and TCR δ chains,
also develop a cytotoxic activity towards cancer cells by recognizing antigens without requiring
their presentation on major histocompatibility complexes. However, in certain cases, they may have
pro-tumoral activities by secreting inflammatory factors such as IL-4, IL-10 and the C-X-C motif
chemokine 13 (CXCL13) [88,89]. In this context, sEVs derived from hypoxic oral cancer cells were
shown to inhibit the expansion and cytotoxicity of γδ T cells, while normoxic sEVs promote it [70].
Interestingly, secretion of perforin, granzyme B and IFN-γ by γδ T cells was decreased after treatment
with hypoxic cancer sEVs via a mechanism involving exosomal miR-21 [70]. The authors demonstrated
that miR-21 exerts its action in myeloid-derived suppressor cells that have a suppressive role towards
γδ T cells, by inhibiting PTEN signaling and decreasing the expression of the programmed death-ligand
1 (PD-L1) at their surface [70]. Furthermore, transfer of sEVs derived from hypoxic nasopharyngeal
carcinoma cells impairs T cell proliferation and differentiation of Th1 and Th17 cells, while it enhances
the differentiation of regulatory T cells (T-reg). This impairment is due to the decrease of fibroblast
growth factor 11 (FGF11) expression levels, which is targeted by the exosomal miR-24-3p [71]. Rong et al.
recently showed that sEVs secreted by hypoxic breast cancer cells inhibit T cell proliferation via TGF-β
expressed at the surface of hypoxic sEVs [49].
Int. J. Mol. Sci. 2020, 21, 5071 9 of 19
Altogether, these findings indicate that sEVs derived from hypoxic cells are implicated in the
downregulation of immune cells, which ultimately benefits cancer cells (Figure 3, Tables 1 and 2).
Figure 3. Hypoxic sEVs modulate the immune system. miR-23a and TGF-β, loaded in hypoxic sEVs,
decrease cytotoxicity of natural killer (NK) cells. The transfer of miR-1246, miR-125b-5p, miR-181d-5p,
miR-21-3p, miR-21-5p, miR-301-3p, miR-940, let7a and/or lncRNA BRCT1 by hypoxic sEVs induce
M2 macrophage polarization. Hypoxic sEVs loaded with miR-10 and miR-21 decrease cytotoxicity of
myeloid derived suppressor cells. Hypoxic sEVs affect the proliferation of T cells and differentiation of
Th1, Th17 and regulatory T cells (T-reg) by transferring miR-21, miR-24-3p and TGF-β.
2.5. Metabolism and Hypoxic Tolerance
Under hypoxia, cells undergo changes in their metabolism, which are elicited by HIF1-α.
In activated hepatic stellate cells, HIF1-α can also be expressed under normoxic conditions and
sEVs derived from those cells can induce a metabolic switch in their surrounding cells [90]. This effect
is due to the transfer of glucose transporter GLUT1 and pyruvate kinase PKM2. The transfer of let7a,
contained in sEVs derived from hypoxic cancer cells, can increase the oxidative phosphorylation in
macrophages [47]. The lncRNA lnc-Ror is enriched in sEVs derived from hypoxic hepatocellular
carcinoma cells and its transfer to normoxic cells triggers an increase in HIF-1α levels and a decrease in
miR-145 levels in the recipient cells [76]. Consequently, Takahashi et al. also demonstrated that the
transfer of lnc-Ror promotes cell survival under hypoxia [76]. Thus, sEVs derived from hypoxic cells
can elicit a metabolic switch and hypoxic tolerance in the target cells, which promotes the progression
of the cancer cells.
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3. sEVs from Hypoxic Cells of the Tumor Microenvironment Influence Growth and Migration of
Cancer Cells
The TME is modulating the progression of cancer cells and sEVs are known to mediate the
communication of cells from the TME and cancer cells [33]. Hypoxic bone-marrow stem cell-released
sEVs transfer miR-193a-3p, miR-210-3p and miR-510, which induce EMT in lung cancer cells through
STAT3 signaling [91]. sEVs derived from hypoxic mesenchymal stem cells transport miR-21-5p and
promote growth and motility of lung cancer cells [85]: miR-21-5p targets PTEN and PDC4 (pyruvate
decarboxylase 4), both inhibiting cancer cell growth. Moreover, miR-21-5p down-regulates expression
of RECK (reversion-inducing cysteine-rich protein with Kazal motifs), thereby impeding cell motility
by inhibiting MMP activity.
Mir-105, which is secreted in sEVs from endothelial cells and which is further upregulated under
hypoxic conditions, participates in the destruction of the vascular endothelial barrier. Therefore,
it helps the dissemination of cancer cells and subsequent metastasis [92]. Release of mitochondrial
DNA (mtDNA) into sEVs derived from fibroblasts can increase oxidative phosphorylation in breast
cancer stem-like cells and this transfer of mtDNA also activates self-renewal of breast cancer stem-like
cells and expedites their resistance to hormonal therapy [93]. Interestingly, release of mtDNA is
induced and increased under hypoxia [94]. These reports all converge on the observation that sEVs
released from hypoxic cells in the TME facilitate the progression of cancer.
4. sEVs Derived from Hypoxic Cells Promote Resistance to Treatment
Hypoxia has been shown to promote resistance to anticancer drug treatments, and sEVs can
play an important role in this process [95,96]. miR-21, by targeting PTEN, promotes resistance to
treatment in various cancer types [72,97]. In lung cancer, miR-21, packed in hypoxic sEVs, confers
resistance to cisplatin [72]. sEVs derived from hypoxic glioma cells deliver miR-301a, which promotes
radiation resistance by downregulating the transcription elongation factor A like 7 (TCEAL7), which is
an inhibitor of the β-catenin/T cell factor (TCF) transcription factor, thus leading to the activation of the
Wnt/β-catenin signaling pathway [73]. In ovarian cancer, sEVs derived from patient-derived ascites
submitted to hypoxia were enriched in STAT3, shown to promote resistance to cisplatin [50].
Resistance to drug treatment can also occur through the efflux of drugs contained in sEVs [98–101].
This effect could be even aggravated under hypoxic conditions, which trigger an increase of sEV
production. However, this remains to be demonstrated and drugs would first have to reach the hypoxic
core of the tumor in order to be loaded in sEVs. In addition, multidrug resistance protein 1 (MDR1)
gene product P-glycoprotein and multidrug resistance-associated protein-1 (MRP1) can be transferred
via sEVs conferring drug resistance to target cells [102–105]. Hypoxia has been shown to increase
P-glycoprotein and MRP1 levels in a HIF-1α -dependent way [106–108] and could thus also lead to
an elevated level of these proteins in sEVs. Protein arginine methyltransferase 5 (PRMT5), which we
have recently found to be enriched in hypoxic melanoma sEVs [22], was shown to be involved in
drug resistance against CDK4/6 inhibitors in melanoma [109]. miR-21, in sEVs from cancer-associated
fibroblasts, can confer resistance to paclitaxel if transferred to ovarian cancer cells [110] and once
again, hypoxia has been demonstrated to induce miR-21 expression [111], potentially also increasing
miR-21 levels in hypoxic sEVs. It remains to be seen if those proteins and/or miRNAs upregulated
under hypoxia in cell lysates, would also be loaded in hypoxic sEVs, as the proteomes and miRNomes
of sEVs often do not completely mirror the proteome and miRNome of the cells from which they
are derived [22]. To this date, there are very few studies investigating the role of hypoxic sEVs in
promoting or transferring drug resistance, but it is likely to assume that the cargo of hypoxic sEVs
is involved in this phenomenon. Toward this end, we have recently identified a truncated form of
anaplastic lymphoma kinase (ALK) transported in sEVs of melanoma cells, which conferred drug
resistance to BRAF inhibitors by activating the MAPK signaling pathway in target cells [112].
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5. sEVs Cargo as Potential Biomarkers
sEVs represent a snapshot of the cells of origin and they can be isolated from patients in a
non-invasive way, which makes them a versatile reservoir carrying potential biomarkers. The content
of hypoxic sEVs could be profiled to indicate stage of disease or possible drug resistance and
could thus help in personalizing treatments. In this context, hypoxic sEVs from melanoma cells
exhibited a signature consisting of 6 proteins (Aldo-Keto reductase family 7 member A2 (AKR7A2)
and DExD-Box Helicase 39B (DDX39B), eukaryotic translation initiation factor 3 subunit C (EIF3C),
phenylalanyl-tRNA synthetase subunit alpha (FARSA), protein arginine methyltransferase 5 (PRMT5)
and valyl-tNRA synthetase (VARS)), which were significantly associated with a poor prognosis for
melanoma patients [22]. However, for routine profiling of sEV content, standardized methods would
have to be agreed on allowing for detection of robust biomarkers. A recent study demonstrated
detection of sEVs without labeling using an electrochemical sensor, to measure an increase of sEVs
secretion under hypoxia from breast cancer cells [113] while the presence of HIF-1α in circulating sEVs
was detected via a colorimetric assay [114]. Remarkably, Wang et al. developed gold nanospheres
linked to a HIF-1α-binding aptamer in order to allow detection of HIF-1α in the 0.3–200 ng L−1
concentration range [114]. Cao et al. identified a sEV-associated gene signature that correlated with
intra-tumoral hypoxic status and predicted recurrence in lung adenocarcinoma [115].
miR-210 and miR-1246 have been discussed as biomarkers for glioma and glioblastoma,
respectively [66,116]. High levels of miR-210 in serum-derived sEVs were associated with high
levels of HIF-1α in glioma patients [116]. In rectal cancer, hypoxia-associated miR-486-5p, miR-181a-5p
and miR-30d-5p were enriched in sEVs from sera of 24 patients and identified as circulating indicators
of high-risk rectal cancer [117]. The levels of miR-24-3p in sEVs were correlated with poor survival of
nasopharyngeal carcinoma patients and therefore, miR-24-3p content in sEVs may serve as a prognostic
biomarker for this type of cancer [71]. An increase of miR-885 and a decrease of miR-521 were
observed in hypoxic sEVs compared to normoxic sEVs derived from pancreatic cells, and importantly,
a similar expression profile was measured in sera from pancreatic cancer patients compared to healthy
individuals [118]. LncRNA-p21 was detected in sEVs derived from lung cancer patients and could
be used as a biomarker for hypoxic sEVs in non-small cell lung cancer [61]. Apart from their use as
biomarkers in cancer, sEV cargos also hold potential in other diseases involving hypoxia: mir-126,
loaded in sEVs isolated from sera of ischemic pre-conditioned patients, could indicate a risk of
ischemic stroke [119]. These data support the notion that hypoxic sEVs represent a promising reservoir
of potential biomarkers for cancer and other diseases. However, it remains to be shown if such
biomarkers are reproducible and if expression patterns are robust enough when using different sEV
isolation methodologies and protein/miRNA detection techniques and following result validation in
independent patient cohorts.
6. Conclusions
sEVs exert a plethora of biological functions, ranging from cellular communication to a reshaping
of the metabolism and the phenotype of the recipient cell. sEVs derived from hypoxic cancer cells
can contribute to an increase of cell proliferation, migration, invasion, EMT and/or angiogenesis.
In addition, they are also involved in drug resistance and mediate immunosuppression. Furthermore,
hypoxic sEVs assist the cells in their adaptation to hypoxia [120]. Many studies have pointed out
the role of miRNAs or proteins carried by hypoxic sEVs in these functions and some recent studies
now also describe the involvement of lncRNAs and other ncRNAs. Furthermore, the role of hypoxic
sEVs derived from stromal or immune cells from the tumor microenvironment is an area of intense
research. Indeed, there is still a lack of evidence whether sEVs produced by hypoxic stromal cells can
reshape the behavior of immune cells or vice versa. In this context, the role of hypoxic sEVs derived
from immune or stromal cells on the modulation of cancer cells is less well understood. If those
sEVs have an important role in tumor progression or regression, it would be of great interest to find
strategies/treatments to modulate these responses. In conclusion, sEVs and in particular hypoxic
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sEVs are important vessels for the transport of bioactive molecules that can exert diverse functions in
target cells and tissues. More refined and standardized techniques would aid the identification and
comparison of profiling data allowing for better exploration of sEV-derived data sets.
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